FDA grants accelerated approval to Gavreto for advanced or metastatic RET-altered thyroid cancers Dec. 2, 2020
Rafael Pharmaceuticals to launch phase II study of CPI-613 in clear cell sarcoma of soft tissue Dec. 2, 2020
Verastem opens phase II study of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer Dec. 1, 2020
Braftovi and Mektovi approved in Japan for additional indication of BRAF-mutant colorectal cancer Dec. 1, 2020
ValiRx presents full updated data from its phase I/II study of VAL-201 in prostate cancer Dec. 1, 2020
RSS